Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Identification of benzoxazine scaffold derivatives as novel CDK4 inhibitors for the treatment of cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer
10.1016/j.bioorg.2022.105659 · 2022 · External reference
From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy
10.1021/acs.jmedchem.1c02064 · 2022 · External reference
Cell cycle kinases as therapeutic targets for cancer
10.1038/nrd2907 · 2009 · External reference
Targeting cell cycle in breast cancer: CDK4/6 Inhibitors
10.3390/ijms21186479 · 2020 · External reference
Targeting CDK4/6 pathways and beyond in breast cancer
10.1016/j.breast.2018.10.001 · 2019 · External reference
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
10.1038/s41388-025-03378-0 · 2025 · External reference
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
2025 · External reference
Efficacy and safety of CDK4/6 inhibitors: a focus on HR+/HER2-early breast cancer
10.1007/s40265-024-02144-y · 2025 · External reference
CDK4 and CDK6 kinases: from basic science to cancer therapy
10.1126/science.abc1495 · 2022 · External reference
Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future
10.1002/phar.1756 · 2016 · External reference
Cancer takes many paths through G1/S
10.1016/j.tcb.2023.10.007 · 2024 · External reference
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
10.1016/s1470-2045(14)71159-3 · 2015 · External reference
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
10.1056/nejmoa1609709 · 2016 · External reference
MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
10.1200/jco.2017.75.6155 · 2017 · External reference
Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences
10.1007/s40265-020-01461-2 · 2021 · External reference
Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic–pharmacodynamic modeling and simulation approach
10.1002/jcph.902 · 2017 · External reference
Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice
10.3389/fonc.2019.00666 · 2019 · External reference
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
10.1182/blood-2014-06-584417 · 2015 · External reference
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
10.1038/s43018-024-00893-z · 2025 · External reference
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
10.1016/j.ccell.2025.02.006 · 2025 · External reference
A CDK4-selective inhibitor puts the brakes on cancer cells
10.1016/j.ccell.2025.02.007 · 2025 · External reference
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+HER2-mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy
10.1200/jco.2023.41.16_suppl.3009 · 2023 · External reference
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2-advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study
10.1016/j.breast.2025.104527 · 2025 · External reference
Discovery of atirmociclib (PF-07220060): a potent and selective CDK4 inhibitor
10.1021/acs.jmedchem.5c02137 · 2025 · External reference
Addressing delivery and resistance issues of CDK4/6 inhibitors as cancer therapeutics
10.1016/j.drudis.2026.104663 · 2026 · External reference
ESR1 mutations: a mechanism for acquired endocrine resistance in breast cancer
10.1038/nrclinonc.2015.117 · 2015 · External reference
The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
10.1158/2159-8290.cd-18-0264 · 2018 · External reference
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: resistance mechanisms and novel treatment strategies
10.1002/cncr.32931 · 2020 · External reference
